The effect of physician diagnostic variability on accuracy at a population level depends on the prevalence of diagnoses.
R
esults of the B-Path (Breast Pathology) Study, an evaluation of diagnostic agreement among pathologists interpreting breast biopsy specimens, indicated marked variability across diagnostic categories (1) . The B-Path Study and others have reported high agreement for slides interpreted as invasive breast cancer or benign cases without atypia but much lower for those interpreted as ductal carcinoma in situ (DCIS) or atypia (1) (2) (3) . These results raise concerns that interpretations of breast biopsy specimens in clinical practice may be inaccurate. For example, 1 of 4 breast biopsy assessments in the B-Path Study disagreed with the expert reference consensus diagnosis. This result was highlighted by the media, with such statements as, "A recent study showed that 25 percent of the time, pathologists disagree with one another in making a diagnosis of cancer" and "as many as one-in-four biopsies are incorrectly diagnosed" (4, 5) .
It would be incorrect to infer that the B-Path Study's overall discordance rate of 25%, based on a test set with 1 slide per case, is an estimate of the expected accuracy of breast pathology in general clinical practice. The study included higher proportions of cases of DCIS and atypia than typically seen in clinical practice, and the overall discordance rate was not intended to reflect population impact. Applying the B-Path Study results to patient populations and communicating the results to patients requires additional analyses that account for population-based prevalence rates for breast biopsy outcomes.
The purpose of this analysis was to estimate the effect of variation in the interpretation of breast biopsy specimens from the perspective of a woman having a biopsy, using U.S. population-adjusted estimates derived from the B-Path Study. This approach provides more clinically relevant estimates of accuracy than previously reported unadjusted estimates.
METHODS

Overview
We estimated the probability that a pathologist's interpretation of a single diagnostically representative breast biopsy slide would be confirmed by a consensus-based reference standard derived from 3 expert breast pathologists interpreting the same slide. For example, if a single slide from a woman's biopsy is interpreted as DCIS, how likely is she to obtain the same diagnosis if a panel of 3 expert pathologists provides a consensus interpretation of the same slide? We calculated the probabilities (predictive values) using Bayes theorem, combining results from the B-Path Study with published data of the prevalence of breast pathology diagnoses in women aged 50 to 59 years from the Breast Cancer Surveillance Consortium (BCSC) (6) . The BCSC is a nationally representative registry of women having mammography in the United States.
The B-Path Study
The B-Path Study invited U.S. pathologists to interpret 1 of 4 test sets of 60 breast biopsy slides (240 total cases, with 1 slide per case). These included 72 benign cases without atypia (24 nonproliferative and 48 proliferative without atypia), 72 with atypia (for example, atypical ductal hyperplasia), 73 with DCIS, and 23 with invasive breast cancer. The proportional representation of these categories differed from population-based prevalence, where most cases are benign without atypia.
Sixty-five percent of invited pathologists who responded were eligible and consented to participate, and 115 completed the study, providing a total of 6900 individual case interpretations. Pathologists were blinded to the interpretations of other study pathologists. Their interpretations were compared with the reference consensus diagnoses, as defined by a panel of 3 experienced breast pathologists who are internationally recognized for research and continuing medical education on diagnostic breast pathology. The 3 panelists reviewed the cases independently and discussed discordant diagnoses by using a multihead microscope to evaluate the cases until a consensus diagnosis was established for each (7, 8) . The reference panel members' concordance with the final consensus diagnoses was 90%, whereas participants' concordance with the same consensus diagnoses was 75%. Unanimous agreement among the 3 reference pathologists' independent diagnoses was 75%, and the average level of unanimous agreement among all possible combinations of 3 participants was 58% (9) .
Prevalence of Breast Pathology Diagnoses
Prevalence rates for each diagnostic category were based on BCSC data from women aged 50 to 59 years who had recent screening mammography (25.1% for invasive breast cancer, 6.1% for DCIS, 3.9% for atypia, and 64.9% for benign cases without atypia) (Appendix, available at www.annals.org) (6) . Prevalence rates by diagnostic category within the B-Path test set and among U.S. women aged 50 to 59 years are shown in Figure 1 .
Statistical Analysis
The predictive value of a given diagnosis is the probability that the diagnosis is correct. In this study, the diagnosis was based on a single slide interpreted by a participating pathologist, with the reference standard being the consensus diagnosis of the 3 expert pathologists interpreting the same slide. Predictive value estimates were based on results of the 115 pathologists' interpretations of the test set cases and the prevalence of biopsy outcomes in the BCSC (6) . Bayes theorem (10) was used to calculate the probability of obtaining a reference consensus diagnosis ("D") given the case interpretation ("T") by a single pathologist, as follows:
is the prevalence of interpretive category "D" (such as DCIS or atypia) among women who have biopsy. Prob[T|D] is the probability that a single slide interpreted by the 3 experts as "D" will be interpreted by a single study pathologist as "T". Prob[T] is equal to Sum (Prob[T|D] × Prob[D]), where "D" represents the reference interpretation and the sum is over all possible interpretive categories for "D". An illustration of the calculation is provided in the Appendix. Because the predictive value is the probability that a diagnosis ("t") will be confirmed by the reference consensus diagnosis, it is calculated as Prob(D=t|T=t).
Probabilities of interpretations by pathologists relative to the reference consensus diagnosis (P[T|D]) were derived from the B-Path Study data and are described in Appendix Tables 1 and 2 (available at www .annals.org). We previously published interpretation rates based on 4 diagnostic categories and used 5 categories in this analysis to further adjust the benign without atypia category using its component outcomes (nonproliferative and proliferative without atypia) (1).
We defined overinterpretation as a diagnosis that was at a higher level of severity than the reference consensus diagnosis and underinterpretation as a diagnosis at a lower level of severity than the reference con-
EDITORS' NOTES Context
Variability in the interpretation of breast biopsy slides has been documented, but its effect at a population level depends on the prevalence of diagnoses.
Contribution
To estimate how diagnostic variability affects accuracy from the perspective of a U.S. woman aged 50 to 59 years having a breast biopsy, researchers compared pathologists' interpretations of a single case slide with a reference consensus interpretation from 3 experts. The likelihood that a diagnosis of atypia or ductal carcinoma in situ (DCIS) would be verified by the reference consensus diagnosis was low.
Caution
Pathologists reviewed a single slide.
Implication
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sensus diagnosis. Overinterpretation rates were 26% for benign nonproliferative, 18% for proliferative without atypia, 17% for atypia, and 3% for DCIS. Underinterpretation rates were 8% for proliferative without atypia, 35% for atypia, 13% for DCIS, and 4% for invasive breast cancer. Because the test set oversampled proliferative cases relative to nonproliferative cases in the benign without atypia category, we calculated the predictive values for 5 diagnostic categories and then collapsed the proliferative and nonproliferative categories into the benign without atypia interpretations. Bootstrapping of data from the B-Path Study was used to calculate CIs for the predictive values by resampling study pathologists randomly and with replacement. Our CIs do not account for sampling variability in the cases.
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RESULTS
When a single slide is used to represent the breast biopsy, population-adjusted predictive value estimates indicate that confirmation of pathologists' interpretations by the expert reference consensus panel would occur in 92.3% (95% CI, 91.4% to 93.1%) of biopsies overall, with 4.6% (CI, 3.9% to 5.3%) overinterpreted and 3.2% (CI, 2.7% to 3.6%) underinterpreted. These estimates assume that the representative diagnostic features of the case are present on the slide examined and do not account for the effect of second opinions that might be obtained in clinical practice.
As noted in Figure 1 , most women having breast biopsy in U.S. clinical practice receive a diagnosis of benign without atypia. For these women, our analysis indicated that diagnostic agreement with the reference panel would be high (97.1% [CI, 96.7% to 97.4%]) (Table 1 and Figures 2 and 3) . Only 2.1% (CI, 1.9% to 2.4%) of the biopsy slides would be interpreted at the higher diagnostic category of atypia by the reference consensus panel, with fewer than 1% interpreted as DCIS (0.6% [CI, 0.5% to 0.7%]) or invasive breast cancer (0.2% [CI, 0.0% to 0.4%]).
Most diagnoses of atypia on a single slide would be overinterpretations by the pathologist; the reference consensus panel would interpret 53.6% (CI, 47.9% to 58.3%) as benign without atypia and 8.6% (CI, 7.0% to 10.5%) as DCIS. The reference panel noted that these DCIS cases would likely be low-grade rather than high-grade DCIS.
For the cases interpreted as DCIS, the reference consensus panel would interpret 9.5% (CI, 5.7% to 13.6%) as benign without atypia, 9.0% (CI, 7.8% to 10.2%) as atypia, and 11.8% (CI, 7.6% to 15.7%) as invasive breast cancer. The last estimate may have been influenced by the presence of 1 case of DCIS with focal microinvasion on the slide that was difficult to identify and was frequently diagnosed as DCIS by study pathologists. The reference panel noted that this microinva- In practice, pathologists often obtain second opinions, and diagnoses that are on the borderline between 2 categories might be factored into treatment decisions. Therefore, diagnostic agreement with the reference consensus panel is shown by whether the pathologist noted that the case was or was not borderline and whether he or she desired a second opinion ( Table 2) . Diagnostic agreement with the reference consensus panel for atypia was less than 50% regardless of the pathologists' desire for a second opinion or whether they noted that the case was borderline. When we restricted the analysis to slides for which pathologists did not consider the case borderline, probabilities of confirmation by the reference consensus panel were 36.8% for atypia and 76.3% for DCIS. When the pathologists did not want a second opinion on the slide, the probability of confirmation was 78.1% for DCIS and 42.5% for atypia.
DISCUSSION
The B-Path Study showed high diagnostic agreement between pathologists and a reference consensus panel of 3 expert breast pathologists for invasive breast cancer but substantially lower agreement for interpretations of DCIS and especially atypia (1) . To extrapolate the B-Path Study results to estimates more relevant to clinical practice, the current analysis included adjustments for prevalence of outcomes in a mammography screening population of women aged 50 to 59 years in the United States. Our results, based on the use of 1 slide per case, suggest that more than 92% of interpretations of breast biopsy specimens in this group of women would be likely to agree with the interpretations of the reference consensus panel. Actual accuracy may be higher due to the effects of obtaining second opinions and context (evaluating >1 slide or special stains).
Although the prevalence of atypia and DCIS diagnoses is low among the total breast biopsies performed each year, the markedly lower diagnostic agreement rates for these categories should not be overlooked or minimized. These noninvasive but potentially high-risk breast lesions represent a gray area with subjective boundaries imposed on a biological continuum; there is not always a "right" or "wrong" diagnosis and, as in many areas of medicine, professional opinions may differ. For women having breast biopsy, our results suggest that nearly 1 in 5 (18.5%) with a diagnosis of DCIS would have her biopsy specimen interpreted as atypia or benign by our reference consensus panel (with the limiting assumptions that the diagnostic features are present on a single slide and no second opinions are obtained).
Overdiagnosis of DCIS has recently been discussed in the literature (11) (12) (13) (14) . The expressed concern is related to increased detection resulting from widespread use of screening mammography. Our results suggest that overinterpretation of the pathologic findings may 
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contribute to overdiagnosis and overtreatment of DCIS. In current practice, most women diagnosed with DCIS are offered lumpectomy and radiation therapy or total mastectomy, and they may also be offered adjuvant hormonal therapy for 5 to 10 years to reduce recurrence risk. Most of the diagnostic variability in pathology is likely due to differentiating atypia from lowgrade DCIS, a diagnostic challenge that may be due to imposing categorical diagnoses on a biological continuum of disease and may not necessarily reflect the accuracy of the pathologist. We also estimated that slightly more than half of breast biopsies with diagnoses of atypia (53.6%) based on a single representative slide would be interpreted as benign cases without atypia by our reference panel. Although diagnostic variability for atypia and DCIS has been noted as a particular challenge for nearly 25 years (2, 3), our prevalence-adjusted estimates shed new Each 100-slide grid demonstrates the predicted number of cases overinterpreted or underinterpreted relative to the reference consensus panel diagnosis, or verified. DCIS = ductal carcinoma in situ. * Interpretation is more severe than the consensus reference panel.
† Interpretation is less severe than the consensus reference panel. Variability in Interpretations of Individual Breast Biopsy Slides ORIGINAL RESEARCH light on potential diagnostic trends at a population level and suggest that higher levels of overinterpretation rather than underinterpretation may occur in practice. The population prevalence of atypia has been estimated to range between 3.9% and 10% of all breast biopsy interpretations in the United States (6, 15) , which equates to a large number of women affected annually given the high number of breast biopsies performed each year. A diagnosis of atypia on a core biopsy has significant implications; atypical ductal hyperplasia has been associated with risk for concurrent and future cancer, and a diagnosis of atypia on a core biopsy is generally followed by an excision biopsy, placement in a high-risk screening group, and consideration for risk-reducing hormonal therapy. Thus, overdiagnosis of atypia may lead to unnecessary surgery, followup, and treatment (16, 17) . The practice of surgical pathology involves systematic sampling of tissue specimens; evaluation of multiple slides; and dynamic opportunities to evaluate additional tissue from paraffin blocks, obtain immunohistochemical or molecular markers, and consult colleagues on challenging cases. The B-Path Study did not evaluate the complete diagnostic pathway but focused on the pathologist first reviewing a case. Thus, the results help to define knowledge gaps on which systemic quality improvements can be built.
Studies of physician diagnostic concordance are challenging to design and implement; perfect simulation of the practice of medicine is rarely possible. The underlying data should be evaluated in context, and their limitations should be considered. In addition to having augmented test cases of atypia and DCIS, the B-Path Study provided data from a testing situation in which pathologists gave interpretations based on only 1 slide per case and were not given the opportunity to obtain additional clinical history, additional testing, or a second opinion from a colleague. However, even in clinical practice, a biopsy diagnosis and recommendation can hinge on a single focus on a single slide, and this was the premise presented to the participating pathologists: Assume that the most diagnostic area for the case is present on the test set slide.
In clinical practice, pathologists are able to obtain second opinions and indicate when they consider diagnoses to be borderline. Participants were asked to record whether a case was on the borderline between 2 diagnoses and to indicate whether they would obtain a second consultative opinion. These data provide additional insight into current practice and opportunities for diagnostic improvement. We calculated the predictive value for interpretations for which pathologists would not desire second opinions and found concerning levels of disagreement with the reference consensus panel for slides showing atypia and DCIS. Similarly, slides that were not considered borderline diagnoses of atypia and DCIS also had high probabilities of not being confirmed by the expert reference consensus panel. Pathologists had higher rates of desiring second opinions or noting a case was borderline when they were less likely to agree with the reference consensus diagnosis, but this was not the case for atypia. Pathologists' diagnoses of atypia had markedly low agreement with the reference standard for all cases, regardless of whether the diagnosis was noted as borderline or the pathologist desired a second opinion.
The B-Path Study reference standard was defined as the consensus diagnosis of 3 experienced breast pathologists. Although the consensus diagnosis may be a reasonable reference standard for a scientific study (9) and, from a patient's perspective, obtaining opinions from 3 experienced pathologists on a case might seem ideal, there is no guarantee that this reference standard represents biological truth. In addition, as stated earlier, differences in diagnostic opinion between 2 or more pathologists may reflect the underlying biological uncertainty inherent in a particular case rather than the diagnostic accuracy of the pathologist. Additional research is needed to determine whether objective measures of diagnostic uncertainty could be integrated into management of breast disease rather than expecting pathologists to always make a definitive microscopic diagnosis.
Our results are based on the limited number of B-Path cases, and histologic data from other populations might differ. We should also note that we used diagnostic prevalence rates based on a population of women in their 50s who were screened using film mammography, and results may differ with newer technologies, such as digital mammography, magnetic resonance imaging, and tomosynthesis. In addition, our estimates may not reflect outcomes for women in other age groups, unscreened women, or women from different countries. Calculations for other populations can be performed by following the example in the Appendix and substituting alternative population-specific prevalence estimates of biopsy outcomes.
In summary, we estimate that the initial interpretation of a single breast biopsy slide with representative diagnostic features would disagree with a reference consensus diagnosis for about 8% of women having a biopsy, with more overinterpretations than underinterpretations among the discordant cases. Of note, more than 97% of interpretations of invasive breast cancer and benign cases without atypia from a single slide would agree with the reference diagnosis, but reference diagnosis verification for DCIS and especially atypia is predicted to be much lower. Efforts to reduce diagnostic variability need to be considered and evaluated and might include educational programs, improved diagnostic techniques, or second-review policies. Alternatively, women with borderline breast lesions that are difficult to categorize, such as atypical ductal hyperplasia and low-grade DCIS, may benefit from revised guidelines for clinical treatment and management given the degree of diagnostic variability and biological overlap between these diagnostic categories. 
